These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 27915425)

  • 21. BCR-ABL in chronic myelogenous leukemia--how does it work?
    Goldman JM; Melo JV
    Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy.
    Mustjoki S; Rohon P; Rapakko K; Jalkanen S; Koskenvesa P; Lundán T; Porkka K
    Leukemia; 2010 Jan; 24(1):219-22. PubMed ID: 19776759
    [No Abstract]   [Full Text] [Related]  

  • 23. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.
    Zámečníkova A
    Expert Rev Hematol; 2010 Feb; 3(1):45-56. PubMed ID: 21082933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.
    Wang W; Cortes JE; Lin P; Khoury JD; Ai D; Tang Z; Tang G; Jorgensen JL; Medeiros LJ; Hu S
    Leukemia; 2015 Nov; 29(11):2263-6. PubMed ID: 25931274
    [No Abstract]   [Full Text] [Related]  

  • 25. The Impact of Variant Philadelphia Chromosome Translocations on the Clinical Course of Chronic Myeloid Leukemia.
    Eyüpoğlu D; Bozkurt S; Haznedaroğlu İ; Büyükaşık Y; Güven D
    Turk J Haematol; 2016 Mar; 33(1):60-5. PubMed ID: 27020722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
    Laneuville P; Dilea C; Yin OQ; Woodman RC; Mestan J; Manley PW
    J Clin Oncol; 2010 Apr; 28(11):e169-71; author reply e172. PubMed ID: 20194843
    [No Abstract]   [Full Text] [Related]  

  • 27. [Management of chronic myeloid leukemia for Japanese patients in the era of TKIs].
    Usui N
    Rinsho Ketsueki; 2014 May; 55(5):497-507. PubMed ID: 24881914
    [No Abstract]   [Full Text] [Related]  

  • 28. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
    Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Implementation of direct sequencing as a method of ABL gene mutations analysis in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor].
    Florek I; Sacha T; Zawada M; Czekalska S; Foryciarz K; Cwynar D; Pecek E; Skotnicki AB
    Przegl Lek; 2010; 67(12):1292-7. PubMed ID: 21591355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antileukemic drug--a selective inhibitor of BCR-ABL tyrosine kynase, imatinib(STI571)].
    Jinnai I
    Nihon Rinsho; 2002 Jan; 60(1):88-94. PubMed ID: 11808344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dasatinib.
    Shah NP
    Drugs Today (Barc); 2007 Jan; 43(1):5-12. PubMed ID: 17315048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glivec and CML: a lucky date.
    Saglio G; Cilloni D; Rancati F; Boano L
    J Biol Regul Homeost Agents; 2004; 18(2):246-51. PubMed ID: 15739279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia.
    Wang D; Zheng Y; Li J; Wu H; Li X; Tang Y; Liu Y; Li J; Sun R; Zhou Y; Sun J; Yang Y
    Eur J Pharmacol; 2017 Sep; 811():117-124. PubMed ID: 28595903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic myelogenous leukemia progenitors display a genetically unstable personality.
    Rodrigues MS; Sattler M
    J Natl Cancer Inst; 2007 May; 99(9):662-3. PubMed ID: 17470729
    [No Abstract]   [Full Text] [Related]  

  • 36. Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease.
    Smith CC; Shah NP
    Hematology Am Soc Hematol Educ Program; 2011; 2011():121-7. PubMed ID: 22160023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Can chronic myeloid leukemia be cured by tyrosine kinase inhibitor?].
    Li MQ; Liu ZG
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):725-8. PubMed ID: 23978030
    [No Abstract]   [Full Text] [Related]  

  • 38. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Characteristics and outcome of chromosomal abnormalities in Ph negative cells of chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors].
    Mu QT; Chen ZM; Lou JY; Cheng YZ; Wang YG; Jin J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Feb; 29(1):64-7. PubMed ID: 22311495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.